TwoStep Therapeutics has raised $62,500,000.00 in New Series A Funding

According to filings with the U.S. Securities and Exchange Commission, TwoStep Therapeutics has raised $62,500,000.00 in new Series A funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Insight Partners and Medical Excellence Capital, with M Ventures (The venture capital arm of Merck KGaA, Darmstadt, Germany) and Pfizer Ventures, NFX and 2048 Ventures

About TwoStep Therapeutics
TwoStep Therapeutics is a biotechnology company focused on developing tumor-targeted therapies for solid tumors using a proprietary polyspecific integrin-binding peptide (PIP) platform that can selectively bind multiple targets highly expressed on solid tumors. By leveraging this multi-targeting peptide, the company aims to overcome the limitations of single-antigen approaches and create a broadly applicable pipeline of targeted cancer therapies for diverse tumor types and patient populations. Its pipeline centers on first-in-class multispecific peptide-drug conjugates and radioligand therapies, with lead programs such as TS-104 advancing toward clinical development and supported by FDA clearance of an Investigational New Drug application. TwoStep is a Stanford University spin-out launched in 2024, co-founded by Nobel Prize winner Carolyn Bertozzi along with Jennifer Cochran, Ron Levy, and CEO Caitlyn Miller, and has secured substantial funding including an oversubscribed $62.5 million Series A and prior seed investment, reflecting strong investor confidence in its technology and strategy. The company, based in San Carlos, California, has also been selected to join Johnson & Johnsons JLABS global incubator network, highlighting its recognition as an innovative player in the targeted oncology space.

To learn more, visit https://twosteptx.com/
Linkedin: https://www.linkedin.com/company/twostep-therapeutics/

Contact:
Caitlyn Miller, Chief Executive Officer
https://www.linkedin.com/in/caitlynmiller3

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.